Physician profile
Bailley A Danforth
NPI 1184348807
$1,053.74
in general payments reported to CMS, 2019-2025
21 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $217 · 2024: $449 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $169.12 | 2023-2025 | |
| Amgen INC. | $132.68 | 2024-2025 | Evenity, Prolia |
| Abbvie INC. | $101.23 | 2024-2025 | |
| Lilly USA, LLC | $100.44 | 2024-2025 | Zepbound, Mounjaro, Basaglar |
| Bayer Healthcare Pharmaceuticals INC. | $99.46 | 2024-2025 | |
| Grifols USA, LLC | $79.03 | 2023-2024 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $46.77 | 2023-2024 | Injectafer |
| Exact Sciences Corporation | $45.97 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $39.06 | 2023 | Xarelto |
| Collegium Pharmaceutical, INC. | $31.21 | 2025 | Jornay Pm |
| Novo Nordisk INC | $27.33 | 2023-2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $25.50 | 2024 | Trintellix |
| Medtronic, INC. | $24.24 | 2024 | Minimed 780g |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.99 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2023 | Ofev |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.89 | 2024 | |
| Merck Sharp & Dohme LLC | $17.38 | 2025 | Vaxneuvance, Capvaxive, Rotateq |
| Glaxosmithkline, LLC. | $15.75 | 2024 | Shingrix, Bexsero, Arexvy |
| Actelion Pharmaceuticals US, INC. | $13.81 | 2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $13.73 | 2024 | Watchman Flx |
| Axonics, INC. | $13.22 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailley Danforth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.